Hale Yapici-Eser1,2, Vivek Appadurai3,4, Candan Yasemin Eren2, Dilek Yazici1, Chia-Yen Chen5,6, Dost Öngür6,7, Diego A Pizzagalli6,8, Thomas Werge3,4,9, Mei-Hua Hall6,7,10. 1. School of Medicine, Koç University, İstanbul, Turkey. 2. Research Center for Translational Medicine, Koç University,İstanbul, Turkey. 3. The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH, Aarhus, Denmark. 4. Institute of Biological Psychiatry, Mental Health Center St. Hans, Mental Health Services Copenhagen, Roskilde, Denmark. 5. Psychiatric and Neurodevelopmental Genetics Unit and Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, USA. 6. Department of Psychiatry, Harvard Medical School, Boston, MA, USA. 7. Schizophrenia and Bipolar Disorder Research Program, McLean Hospital, Belmont, MA, USA. 8. Center for Depression, Anxiety and Stress Research, McLean Hospital, Belmont, MA, USA. 9. Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. 10. Psychosis Neurobiology Laboratory, McLean Hospital, Harvard Medical School, Belmont, MA, USA.
Abstract
BACKGROUND: Glucagon-like peptide-1 receptors (GLP-1Rs) are widely expressed in the brain. Evidence suggests that they may play a role in reward responses and neuroprotection. However, the association of GLP-1R with anhedonia and depression diagnosis has not been studied. Here, we examined the association of GLP-1R polymorphisms with objective and subjective measures of anhedonia, as well as depression diagnosis. METHODS: Objective [response bias assessed by the probabilistic reward task (PRT)] and subjective [Snaith-Hamilton Pleasure Scale (SHAPS)] measures of anhedonia, clinical variables and DNA samples were collected from 100 controls and 164 patients at McLean Hospital. An independent sample genotyped as part of the Psychiatric Genomics Consortium (PGC) was used to study the effect of putative GLP-1R polymorphisms linked to response bias in PRT on depression diagnosis. RESULTS: The C allele in rs1042044 was significantly associated with increased PRT response bias, when controlling for age, sex, case-control status and PRT discriminability. AA genotype of rs1042044 showed higher anhedonia phenotype based on SHAPS scores. However, analysis of PGC major depressive disorder data showed no association between rs1042044 and depression diagnosis. CONCLUSION: Findings suggest a possible association of rs1042044 with anhedonia but no association with depression diagnosis.
BACKGROUND:Glucagon-like peptide-1 receptors (GLP-1Rs) are widely expressed in the brain. Evidence suggests that they may play a role in reward responses and neuroprotection. However, the association of GLP-1R with anhedonia and depression diagnosis has not been studied. Here, we examined the association of GLP-1R polymorphisms with objective and subjective measures of anhedonia, as well as depression diagnosis. METHODS: Objective [response bias assessed by the probabilistic reward task (PRT)] and subjective [Snaith-Hamilton Pleasure Scale (SHAPS)] measures of anhedonia, clinical variables and DNA samples were collected from 100 controls and 164 patients at McLean Hospital. An independent sample genotyped as part of the Psychiatric Genomics Consortium (PGC) was used to study the effect of putative GLP-1R polymorphisms linked to response bias in PRT on depression diagnosis. RESULTS: The C allele in rs1042044 was significantly associated with increased PRT response bias, when controlling for age, sex, case-control status and PRT discriminability. AA genotype of rs1042044 showed higher anhedonia phenotype based on SHAPS scores. However, analysis of PGC major depressive disorder data showed no association between rs1042044 and depression diagnosis. CONCLUSION: Findings suggest a possible association of rs1042044 with anhedonia but no association with depression diagnosis.
Authors: Jan Detka; Joanna Ślusarczyk; Anna Kurek; Mateusz Kucharczyk; Tomasz Adamus; Paweł Konieczny; Marta Kubera; Agnieszka Basta-Kaim; Władysław Lasoń; Bogusława Budziszewska Journal: Pharmacol Rep Date: 2018-11-27 Impact factor: 3.024
Authors: Haroon I Sheikh; Lea R Dougherty; Elizabeth P Hayden; Daniel N Klein; Shiva M Singh Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2010-05-16 Impact factor: 5.067
Authors: Diego A Pizzagalli; Dan Iosifescu; Lindsay A Hallett; Kyle G Ratner; Maurizio Fava Journal: J Psychiatr Res Date: 2008-04-22 Impact factor: 4.791
Authors: Mark S Gold; Kenneth Blum; Marcelo Febo; David Baron; Edward Justin Modestino; Igor Elman; Rajendra D Badgaiyan Journal: Front Biosci (Schol Ed) Date: 2018-03-01
Authors: Diana L Williams; Nicole A Lilly; Ian J Edwards; Pallas Yao; James E Richards; Stefan Trapp Journal: Neuropharmacology Date: 2017-12-06 Impact factor: 5.250